Corinna Warburton

1.4k citations

16 papers · 1.1k indexed · 1 hit paper · h-index 13

Molecular Biology
Endocrinology, Diabetes and Metabolism top 5%
Genetics top 10%
Oncology
Epidemiology

Co-authors: Lyn Powell-Braxton Mary Dowd Sharon Pitts-Meek Philip G. Hollingshead Dyana K. Dalton Nancy A. Gillett Timothy A. Stewart Marcel B. Bally
Topics: Monoclonal and Polyclonal Antibodies Research (4 papers)HER2/EGFR in Cancer Research (3 papers)Glycosylation and Glycoproteins Research (2 papers)
Cited by: Endocrinology, Diabetes and Metabolism Molecular Biology Cancer Research
Journals: Genes & Development PLoS ONE Cancer Research
Partner nations: Canada France Netherlands

In The Last Decade

Corinna Warburton

16 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IGF-I is required for normal embryonic growth in mice.

1993 635 citations Lyn Powell-Braxton, Philip G. Hollingshead et al. Genes & Development profile →

Peers

Countries citing papers authored by Corinna Warburton

Since Specialization

Citations

This map shows the geographic impact of Corinna Warburton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Corinna Warburton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Corinna Warburton more than expected).

Fields of papers citing papers by Corinna Warburton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Corinna Warburton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Corinna Warburton. The network helps show where Corinna Warburton may publish in the future.

Co-authorship network of co-authors of Corinna Warburton

This figure shows the co-authorship network connecting the top 25 collaborators of Corinna Warburton. A scholar is included among the top collaborators of Corinna Warburton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Corinna Warburton. Corinna Warburton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	In Vivo Validation of PAPSS1 (3′-phosphoadenosine 5′-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target 2017 ·Clinical Cancer Research ·Ada W.Y. Leung,Chansey J. Veinotte,(unknown),Min Hee Oh,(unknown),Katey S.S. Enfield,Ian Backstrom,Corinna Warburton,Donald T. Yapp,Jason N. Berman,Marcel B. Bally,William W. Lockwood	9
2	Abstract 3792: PAPSS1 (3’-phosphoadenosine 5’-phosphosulfate synthase 1) inhibition sensitizes non-small cell lung cancer to cisplatin treatment in vivo 2016 ·Cancer Research ·Ada W.Y. Leung,Chansey J. Veinotte,(unknown),Ian Backstrom,Corinna Warburton,Edie Dullaghan,Jason N. Berman,Marcel B. Bally	1
3	3′-Phosphoadenosine 5′-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents 2015 ·Oncotarget ·Ada W.Y. Leung,Wieslawa H. Dragowska,(unknown),Brian Kwok,Veena Mathew,(unknown),(unknown),Corinna Warburton,Janessa Laskin,Peter C. Stirling,Mohammed A. Qadir,Marcel B. Bally	19
4	Induction of Autophagy Is an Early Response to Gefitinib and a Potential Therapeutic Target in Breast Cancer 2013 ·PLoS ONE ·Wieslawa H. Dragowska,Sherry A. Weppler,(unknown),(unknown),Anita I. Kapanen,(unknown),Corinna Warburton,Mohammed A. Qadir,Elizabeth Donohue,Michel Roberge,Sharon M. Gorski,Karen A. Gelmon,Marcel B. Bally	91
5	Combined RNAi-Mediated Suppression of Rictor and EGFR Resulted in Complete Tumor Regression in an Orthotopic Glioblastoma Tumor Model 2013 ·PLoS ONE ·Maïté Verreault,Sherry A. Weppler,(unknown),Corinna Warburton,(unknown),Dana Masin,Marcel B. Bally	25
6	Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267 2011 ·Cancer Biology & Therapy ·Jessica Kalra,Malathi Anantha,Corinna Warburton,Dawn Waterhouse,Hong Yan,Young Joo Yang,(unknown),(unknown),Dana Masin,Marcel B. Bally	16
7	QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model 2009 ·Breast Cancer Research ·Jessica Kalra,Corinna Warburton,(unknown),Lincoln Edwards,(unknown),Dawn Waterhouse,Wieslawa H. Dragowska,Brent W. Sutherland,Shoukat Dedhar,Karen A. Gelmon,Marcel B. Bally	61
8	Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs 2007 ·Molecular Cancer Therapeutics ·Gigi N.C. Chiu,Lincoln Edwards,Anita I. Kapanen,Melina M. Malinen,Wieslawa H. Dragowska,Corinna Warburton,Ghania Chikh,(unknown),Sophia T. Tan,(unknown),(unknown),Dawn Waterhouse,Richard Klasa,Marcel B. Bally	51
9	Treatment with a Cholesterol Absorption Inhibitor (FM-VP4) Reduces Body Mass and Adipose Accumulation in Developing and Pre-Obese Mice 2007 ·Drug Development and Industrial Pharmacy ·Sheila J. Thornton,Corinna Warburton,Kishor M. Wasan,Piotr Kozłowski	11
10	Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin 2007 ·Breast Cancer Research and Treatment ·Wieslawa H. Dragowska,Maïté Verreault,Donald T. Yapp,Corinna Warburton,Lincoln Edwards,Euan C. Ramsay,Lynsey A. Huxham,Andrew I. Minchinton,Karen A. Gelmon,Marcel B. Bally	15
11	Leishmania majorAbrogates Gamma Interferon-Induced Gene Expression in Human Macrophages from a Global Perspective 2007 ·Infection and Immunity ·(unknown),Corinna Warburton,W. Robert McMaster	40
12	HER-2/neuOverexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization 2004 ·Molecular Cancer Research ·Wieslawa H. Dragowska,Corinna Warburton,Donald T. Yapp,Andrew I. Minchinton,Yanping Hu,Dawn Waterhouse,Karen A. Gelmon,Kirsten A. Skov,Janet Woo,Dana Masin,Lynsey A. Huxham,Alastair H. Kyle,Marcel B. Bally	23
13	Treatment of HER-2/ *neu* Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/ *neu* and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction 2004 ·Clinical Cancer Research ·Corinna Warburton,Wieslawa H. Dragowska,Karen A. Gelmon,Stephen Chia,(unknown),Dana Masin,(unknown),(unknown),Marcel B. Bally	60
14	Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials 2004 ·Vaccine ·Noushin Davoudi,(unknown),Corinna Warburton,(unknown),Fereidoun Mahboudi,W. Robert McMaster	30
15	Mouse models of IGF-I deficiency generated by gene targeting. 1995 ·PubMed ·Corinna Warburton,Lyn Powell-Braxton	13
16	IGF-I is required for normal embryonic growth in mice.breakdown → 1993 ·Genes & Development ·Lyn Powell-Braxton,Philip G. Hollingshead,Corinna Warburton,Mary Dowd,Sharon Pitts-Meek,Dyana K. Dalton,Nancy A. Gillett,Timothy A. Stewart	635

About Corinna Warburton

Corinna Warburton is a scholar working on Cancer Research, Radiology, Nuclear Medicine and Imaging and Immunology and Allergy, having authored 16 papers that have together received 1.1k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (4 papers), HER2/EGFR in Cancer Research (3 papers) and Glycosylation and Glycoproteins Research (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (384 citations), Molecular Biology (649 citations) and Cancer Research (124 citations). Corinna Warburton has collaborated with scholars based in Canada, France and Netherlands. Frequent co-authors include Lyn Powell-Braxton, Mary Dowd, Sharon Pitts-Meek, Philip G. Hollingshead, Dyana K. Dalton, Nancy A. Gillett, Timothy A. Stewart, Marcel B. Bally, Wieslawa H. Dragowska and Karen A. Gelmon. Their work appears in journals such as Genes & Development, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact